4-Methylmorpholine → N-({4-[(2R,3R)-3-{[2-(1,3-benzodioxol-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-D-lysine

HRID 603905ノート

反応式

HRID 603905 の反応式
[O:1]1[C:5]2[CH:6]=[CH:7][C:8]([CH:10]([OH:40])[CH2:11][S:12][C@H:13]3[C:16](=[O:17])[N:15]([C:18]4[CH:23]=[CH:22][C:21]([F:24])=[CH:20][CH:19]=4)[C@@H:14]3[C:25]3[CH:39]=[CH:38][C:28]([O:29][CH2:30][C:31]([NH:33]CC(O)=O)=[O:32])=[CH:27][CH:26]=3)=[CH:9][C:4]=2[O:3][CH2:2]1.Cl.C(OC(NCCCC[C@H](C(OC(C)(C)C)=O)N)=O)(C)(C)C.CN1CCOCC1.CN(C(ON1N=NC2C=CC=CC1=2)=[N+](C)C)C.[B-](F)(F)(F)F.O1C2C=CC(C(O)CS[C@H]3C(=O)N(C4C=CC(F)=CC=4)[C@@H]3C3C=CC(OCC(N[CH2:125][C:126]([NH:128][C@@H:129]([C:142]([O:144]C(C)(C)C)=[O:143])[CH2:130][CH2:131][CH2:132][CH2:133][NH:134]C(OC(C)(C)C)=O)=[O:127])=O)=CC=3)=CC=2OC1>C(Cl)Cl>[O:1]1[C:5]2[CH:6]=[CH:7][C:8]([CH:10]([OH:40])[CH2:11][S:12][C@H:13]3[C:16](=[O:17])[N:15]([C:18]4[CH:23]=[CH:22][C:21]([F:24])=[CH:20][CH:19]=4)[C@@H:14]3[C:25]3[CH:26]=[CH:27][C:28]([O:29][CH2:30][C:31]([NH:33][CH2:125][C:126]([NH:128][C@@H:129]([C:142]([OH:144])=[O:143])[CH2:130][CH2:131][CH2:132][CH2:133][NH2:134])=[O:127])=[O:32])=[CH:38][CH:39]=3)=[CH:9][C:4]=2[O:3][CH2:2]1

参加物

7

反応物 5

HCID 79724-MethylmorpholineHCID 2733207O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborateHCID 56777341H-D-Lys(boc)-otbu hclHCID 67270896tert-butyl N-({4-[(2R,3R)-3-{[2-(1,3-benzodioxol-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-N6-(tert-butoxycarbonyl)-D-lysinateHCID 67271334N-({4-[(2R,3R)-3-{[2-(1,3-benzodioxol-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycine

生成物 1

HCID 67271513N-({4-[(2R,3R)-3-{[2-(1,3-benzodioxol-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-D-lysine

試薬・触媒・溶媒 1

HCID 6344Dichloromethane溶媒

実験手順

To a stirred solution of N-({4-[(2R,3R)-3-{[2-(1,3-benzodioxol-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycine (11.3 mg, 0.020 mmol) in DCM (2 ml) were added tert-butyl N6-(tert-butoxycarbonyl)-D-lysinate hydrochloride (9.5 mg, 0.028 mmol), N-methylmorpholine (15 μl, 0.091 mmol) and TBTU (11.0 mg, 0.034 mmol). The reaction mixture was stirred at ambient temperature for 3 hours. The formation of the intermediate tert-butyl N-({4-[(2R,3R)-3-{[2-(1,3-benzodioxol-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-N6-(tert-butoxycarbonyl)-D-lysinate was confirmed. M/z: 852.23 (M−1). The solvent was removed under reduced pressure and the residue was dissolved in formic acid (2 ml). The mixture was stirred at ambient temperature for 48 hours. The solvent was co-evaporated with toluene and the residue was purified with preparative HPLC on a C8 column, UV 240/260 nm. A gradient from 20 to 45% MeCN in 0.1M NH4OAc buffer was used as eluent. The MeCN was removed under reduced pressure and the residue was lyophilised to give the title. H-NMR (400 MHz, DMSO-d6): 1.08-1.32 (m, 2H), 1.37-65 (m, 4H), 2.63 (t, 2H), 2.77-2.92 (m, 2H), 3.70 (d, 2H), 3.76-3.82 (m, 1H), 4.25 (d, 0.5H), 4.28 (d, 0.5H), 4.50 (s, 2H), 4.57-4.64 (m, 1H), 5.00 (d, 0.5H), 5.02 (d, 0.5H), 5.90-5.94 (m, 2H), 6.70-6.81 (m, 2H), 6.83 (s, 1H), 6.96 (d, 2H), 7.08-7.16 (m, 2H), 7.17-7.24 (m, 2H), 7.34 (d, 2H), 7.45-7.55 (m, 1H), 8.37-8.43 (m, 1H). M/z: 697.32 (M+1) and 695.39 (M−1).

後処理

  1. customThe solvent was removed under reduced pressure
  2. dissolutionthe residue was dissolved in formic acid (2 ml)
  3. stirringThe mixture was stirred at ambient temperature for 48 hours
  4. customthe residue was purified with preparative HPLC on a C8 column, UV 240/260 nm
  5. customThe MeCN was removed under reduced pressure
  6. customto give the title

出典と根拠

ORDレコード
ord-f2c26b6e1ca447fe99f4d27a77219e1a
出典データセット
uspto-grants-2011_03
特許番号
US07906502B2

反応ノート

読み込み中…